Peptide pills for brain diseases? Reality and future perspectives

Area of Science:

• Pharmaceutical Science
• Nanomedicine
• Neuroscience

Background:

• The peptide therapeutic market is rapidly expanding, yet oral delivery to the central nervous system (CNS) remains a significant unmet need.
• Current treatments for CNS disorders often require parenteral administration due to the blood-brain barrier (BBB) and peptide instability.
• No oral peptide therapeutics are currently approved for CNS disorders, highlighting a critical gap in treatment options.

Purpose of the Study:

• To review the challenges and advancements in oral peptide delivery for CNS disorders.
• To evaluate the potential of nanoparticulate strategies in overcoming biological barriers for brain-targeted peptide therapeutics.
• To discuss the future outlook for developing oral peptide nanomedicines for neurological conditions.

Main Methods:

• Literature review of existing peptide therapeutics and delivery systems.
• Analysis of challenges including enzymatic degradation and BBB penetration.
• Evaluation of nanoparticulate systems for oral peptide bioavailability and brain targeting.

Main Results:

• Oral administration of peptides to the brain is hindered by enzymatic instability and poor permeation across physiological barriers.
• Nanoparticulate strategies have demonstrated potential in delivering therapeutic peptides orally to the brain.
• Parenteral administration remains the standard due to the BBB's exclusion of most molecules.

Conclusions:

• Nanoparticulate drug delivery systems offer a viable strategy for overcoming barriers to oral peptide delivery to the brain.
• Despite industry reluctance, the unmet clinical need for CNS disorder treatments will likely drive the development of oral peptide nanomedicines.
• The first marketed oral-to-brain peptide therapy is anticipated, addressing a critical gap in neurological treatment.